恶性葡萄胎患者化疗前后血清SOD、SIL-2R和IGF-Ⅱ检测的临床意义

Clinical Significance of Determination of Changes of Serum SOD,SIL-2R and IGF-Ⅱ Levels After Chemotherapy in Patients with Malignant Hydatidiform Mole

目的:探讨了恶性葡萄胎患者化疗前后血清SOD、SIL-2R和IGF-Ⅱ检测的临床意义。方法:应用放射免疫分析和酶联法对31例恶性葡萄胎患者进行了血清SOD、SIL-2R和IGF-Ⅱ检测,并与35名正常健康人做比较。结果:恶性葡萄胎患者在化疗前血清SOD水平显著低于正常人组(P<0.01),而血清SIL-2和IGF-Ⅱ水平又非常显著地高于正常人组(P<0.01)。化疗后6个月与正常人组比较仍有显著性差异(P<0.05)。血清SOD水平与SIL-2R和IGF-Ⅱ水平呈显著负相关(r=-0.5138、-0.4928,P<0.01)。结论:检测恶性葡萄胎患者血清SOD、SIL-2R和IGF-Ⅱ水平的变化,对观察疗效和预后有一定的临床使用价值。

Objective To study the clinical significance of changes on serum SOD,SIL-2R and IGF-Ⅱ levels after chemotherapy in patients with malignant hydatidiform mole.Methods Serum SOD,IGF-Ⅱ（with RIA） and SIL-2R（with ELISA） levels were measured both before and after chemotherapy in 31 patients with malignant hydatidiform mole as well as in 35 normal controls.Results Before chemotherapy serum SOD levels were significantly lower in the patients than those in controls（P0.01）.While the serum SIL-2R and IGF-Ⅱ levels were notably higher（P0.01）.Six month after chemotherapy the levels changed markedly toward normal,but remained obviously different from those in normal controls（P0.05）.The levels of serum SOD were negatively correlated with SIL-2R,IGF-Ⅱ（r=-0.5138,-0.4928,P0.01）.Conclusion Detection of serum SOD,SIL-2R and IGF-Ⅱ levels provides clinical value for curative effect and prognosis in patients with malignant hydatidiform mole.